Single-dose pharmacokinetics of nizatidine (Axid®) in children

Journal of Clinical Pharmacology

Volumn 42, Issue 10, 2002, Pages 1089-1096

  Abdel Rahman, Susan M ^a,b,c   Johnson, Franklin K ^d   Manowitz, Neil ^d   Holmes, Gregory B ^e   Kearns, Gregory L ^a,b,c  

^a CHILDREN S MERCY HOSPITAL   (United States)

^b Department of Pediatrics ^*  (United States)

^c UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^d Reliant Pharmaceuticals LLC   (United States)

^e SFBC International   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

N NORNIZATIDINE; NIZATIDINE; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; CHILD; CLINICAL ARTICLE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG FORMULATION; DRUG METABOLISM; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; STOMACH ACID SECRETION;

ADMINISTRATION, ORAL; AREA UNDER CURVE; CHILD; CHILD, PRESCHOOL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HALF-LIFE; HISTAMINE H2 ANTAGONISTS; HUMANS; INFANT; MALE; NIZATIDINE;

EID: 0036785485     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/009127002401382687     Document Type: Article

References (27)

1. Thompson A, Kirdeikis P, Jamali F, Tavernini M, Zuk L, Marriage B, et al: Effect of nizatidine and ranitidine on 24 hour intragastric pH, pepsin, prostaglandin E2 and serum gastrin concentrations in healthy volunteers. J Gastroenterol Hepatol 1995;10:546-554.
2. Spiegel JE, Thoden WR, Pappas K, Fratarcangelo P, Furey SA: A double-blind, placebo-controlled study of the effectiveness and safety of nizatidine in the prevention of postprandial heartburn. Arch Intern Med 1997;157:1594-1599.
3. Thomson AB, Mahachai V, Bailey RJ, Kirdeikis P, Zuk L. Marriage B, et al: Twice daily nizatidine or ranitidine is superior to once daily dosing in elevating 24 h intragastric pH in patients with duodenal ulcer disease. J Gastroenterol Hepatol 1996;11:1171-1176.
4. Cloud ML, Offen WW: Nizatidine versus placebo in gastrooesophageal reflux disease: a 6-week, multicentre, randomised, double-blind comparison. Br J Clin Pract Suppl 1994;76:11-19.
5. Cloud ML, Offen WW, Robinson M: Nizatidine versus placebo in gastro-oesophageal reflux disease: a 12-week, multicentre, randomised, double-blind study. Br J Clin Pract Suppl 1994;76:3-10.
6. Axid® prescribing information, in: Physicians' Desk Reference. 56th ed. Montvale, NJ: Medical Economics Co., 2002.
7. Lin JH: Pharmacokinetic and pharmacodynamic properties of histamine H2-receptor antagonists: relationship between intrinsic potency and effective plasma concentrations. Clin Pharmacokinet 1991;20:218-236.
8. Furuta S, Kamada E, Suzuki T, Sugimoto T, Kawabata Y, Shinozaki Y, Sano H: Inhibition of drug metabolism in human liver microsomes by nizatidine, cimetidine and omeprazole. Xenobiotica 2001;31:1-10.
9. Eland IA, Alvarez CH, Stricker BH, Rodriguez LA: The risk of acute pancreatitis associated with acid-suppressing drugs. Br J Clin Pharmacol 2000;49:473-478.
10. Vandenplas Y, Hegar B: Diagnosis and treatment of gastrooesophageal reflux disease in infants and children. J Gastroenterol Hepatol 2000;15:593-603.
11. Mezoff AG, Balistreri WF: Peptic ulcer disease in children. Pediatr Rev 1995;16:257-265.
12. Kelly DA: Do H2 receptor antagonists have a therapeutic role in childhood? J Pediatr Gastroenterol Nutr 1994;19:270-276.
13. George DE, Glassman M: Peptic ulcer disease in children. Gastrointest Endosc Clin N Am 1994;4:23-37.
14. Behrens R, Hofbeck M, Singer H, Scharf J, Rupprecht T: Frequency of stress lesions of the upper gastrointestinal tract in paediatric patients after cardiac surgery: effects of prophylaxis. Br Heart J 1994;72:186-189.
15. James LP, Marshall JD, Heulitt MJ, Wells TG, Letzig L, Kearns GL: Pharmacokinetics and pharmacodynamics of famotidine in children. J Clin Pharmacol 1996;36:48-54.
16. James LP, Marotti T, Stowe CD, Farrar HC, Taylor BJ, Kearns GL: Pharmacokinetics and pharmacodynamics of famotidine in infants. J Clin Pharmacol 1998;38:1089-1095.
17. Murphy MG, James LP, Wenning LA, Blumer JL, Panebianco D, Yeh K, Kearns GL: Famotidine pharmacokinetics in infants. Clin Pharmacol Ther 2001;69:80.
18. Simeone D, Caria MC, Miele E, Staiano A: Treatment of childhood peptic esophagitis: a double-blind placebo-controlled trial of nizatidine. J Pediatr Gastroenterol Nutr 1997;25:51-55.
19. Mikawa K, Nishina K, Maekawa N, Takao Y, Obara H: Effects of oral nizatidine on preoperative gastric fluid pH and volume in children. Br J Anaesth 1994;73:600-604.
20. Lantz MD, Wozniak TJ: Stability of nizatidine in extempornaeous oral liquid preparations. Am JHosp Pharm 1990;47:2716-2719.
21. Jamali F, Thomson AB, Kirdeikis P, Tavernini M, Zuk L, Marriage B, et al: Diurnal variation in the pharmacokinetics of nizatidine in healthy volunteers and in patients with peptic ulcer disease. J Clin Pharmacol 1995;35:1071-1075.
22. MDS Pharma Services, Inc.: Validation of a high performance liquid chromatographic mass spectrometric method for the determination of nizatidine and N-desmethyl nizatidine in human plasma (EDTA). MDSPS Project No. 90187/PIM.
23. Schneck DW, Callaghan JT, Bergstrom RF, Obermeyer BD, Offen WW: Relationship between steady-state plasma nizatidine concentrations and inhibition of basal and stimulated gastric acid secretion. Clin Pharmacol Ther 1990;47:499-503.
24. 2-blocker: its metabolism and disposition in man. Drug Metab Dispos 1986;14:175-182.
25. Pediatric pharmacokinetics, in: Ritschel WA, Kearns GL (eds.), Handbook of Basic Pharmacokinetics. 5th ed, Washington, DC: American Pharmaceutical Association, 1999;304-321.
26. Knadler MP, Rubin A, Bergstrom RF. Callaghan JT: Effects of gelusil (g), charcoal (c), and propantheline (p) on the bioavailability of the H2-blocker nizatidine (n). Pharmacologist 1984;26:236.
27. Kearns GL: Impact of developmental pharmacology on pediatric study design: overcoming the challenges. J Allergy Clin Immunol 2000;106:S128-S138.